JP2021517894A5 - - Google Patents
Info
- Publication number
- JP2021517894A5 JP2021517894A5 JP2020548775A JP2020548775A JP2021517894A5 JP 2021517894 A5 JP2021517894 A5 JP 2021517894A5 JP 2020548775 A JP2020548775 A JP 2020548775A JP 2020548775 A JP2020548775 A JP 2020548775A JP 2021517894 A5 JP2021517894 A5 JP 2021517894A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- composition according
- pharmaceutical composition
- cancer
- cdk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025013551A JP2025069282A (ja) | 2018-03-13 | 2025-01-30 | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642472P | 2018-03-13 | 2018-03-13 | |
| US62/642,472 | 2018-03-13 | ||
| PCT/US2019/022067 WO2019178239A1 (en) | 2018-03-13 | 2019-03-13 | Methods for treatment of cancers with egfr activating mutations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013551A Division JP2025069282A (ja) | 2018-03-13 | 2025-01-30 | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517894A JP2021517894A (ja) | 2021-07-29 |
| JP2021517894A5 true JP2021517894A5 (https=) | 2022-03-22 |
| JP7698418B2 JP7698418B2 (ja) | 2025-06-25 |
Family
ID=67908486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548775A Active JP7698418B2 (ja) | 2018-03-13 | 2019-03-13 | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
| JP2025013551A Withdrawn JP2025069282A (ja) | 2018-03-13 | 2025-01-30 | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013551A Withdrawn JP2025069282A (ja) | 2018-03-13 | 2025-01-30 | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210015819A1 (https=) |
| JP (2) | JP7698418B2 (https=) |
| KR (1) | KR20200132902A (https=) |
| CN (1) | CN111867586A (https=) |
| WO (1) | WO2019178239A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816437B (zh) | 2016-03-29 | 2018-08-03 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
| EP4192463A1 (en) * | 2020-08-07 | 2023-06-14 | Hope Permanente, LLC | Use of cyclin-dependent kinase (cdk) inhibitors for the slowdown or prevention of biological aging |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| CN114432454B (zh) * | 2022-03-21 | 2023-05-05 | 安徽大学 | Plk1抑制剂在制备治疗埃博拉病毒疾病的药物中的应用 |
| CN119137102A (zh) | 2022-04-08 | 2024-12-13 | 拜奥列司治疗有限公司 | Cdk9抑制剂 |
| CN117045660A (zh) * | 2022-04-22 | 2023-11-14 | 南京市儿童医院 | 一种plk1抑制剂在制备用于缓解肾脏纤维化药物中的用途 |
| WO2024192141A1 (en) * | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
| WO2025245045A1 (en) * | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101313702B1 (ko) * | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| US8399442B2 (en) * | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| BRPI0707580A2 (pt) | 2006-02-10 | 2011-05-10 | Nerviano Medical Sciences Srl | combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico |
| GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
| AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| EP2224919A4 (en) * | 2007-11-28 | 2011-09-14 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES |
| WO2009114703A2 (en) | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20140155397A1 (en) * | 2011-04-01 | 2014-06-05 | Board Of Regents | Emt signatures and predictive markers and method of using the same |
| PL2838998T3 (pl) * | 2012-04-18 | 2018-04-30 | Cell Signaling Technology, Inc. | EGFR i ROS1 w nowotworze |
| BR102013027577A2 (pt) * | 2012-10-25 | 2016-03-29 | Memorialsloan Kettering Cancer Ct | método de detecção de um nível aumentado de axl ou gas6 e método de identificação de um paciente com câncer resistente a inibidor de egfr |
| WO2015095840A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
| WO2015112705A2 (en) * | 2014-01-24 | 2015-07-30 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
| US20160346240A1 (en) * | 2014-02-03 | 2016-12-01 | Quadriga Biosciences, Inc. | Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs |
| US10555931B2 (en) * | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
| WO2016201370A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US10240145B2 (en) * | 2015-11-25 | 2019-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer |
| GB201612520D0 (en) * | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| US20190275049A1 (en) * | 2016-11-16 | 2019-09-12 | Pfizer Inc. | Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| WO2019090332A1 (en) * | 2017-11-06 | 2019-05-09 | Tiziana Life Sciences Plc | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
-
2019
- 2019-03-13 WO PCT/US2019/022067 patent/WO2019178239A1/en not_active Ceased
- 2019-03-13 JP JP2020548775A patent/JP7698418B2/ja active Active
- 2019-03-13 US US16/980,079 patent/US20210015819A1/en active Pending
- 2019-03-13 CN CN201980018745.1A patent/CN111867586A/zh active Pending
- 2019-03-13 KR KR1020207028689A patent/KR20200132902A/ko not_active Ceased
-
2025
- 2025-01-30 JP JP2025013551A patent/JP2025069282A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517894A5 (https=) | ||
| Grech et al. | EPMA position paper in cancer: current overview and future perspectives | |
| Kodaz et al. | Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer | |
| JP2022529016A5 (https=) | ||
| JP2022527788A5 (https=) | ||
| JP2022515705A (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法 | |
| BR112016008016B1 (pt) | Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditoscompostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ounras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dosditos compostos | |
| CN104781423A (zh) | 对胃癌进行分类的分组方法 | |
| CA2850175C (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| Huang et al. | CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation | |
| CN114540500A (zh) | 评价乳腺癌患者整体生存的产品 | |
| JP2022527499A5 (https=) | ||
| JP2021519306A5 (https=) | ||
| US20220305008A1 (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| JP2022515128A5 (https=) | ||
| JP2007513967A (ja) | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 | |
| Liu et al. | Novel targeted agents for the treatment of lung cancer in China | |
| Martinelli et al. | New targets for Ph+ leukaemia therapy | |
| Kozlov et al. | Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report | |
| Chen et al. | The signature of immune-subtype specific driving transcription factors suggest potential drugs for refractory glioblastoma | |
| Jin-Fei et al. | Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer. | |
| Su et al. | Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China | |
| CN107841793A (zh) | 肺癌多基因突变文库的构建方法 | |
| Sun et al. | NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma | |
| CN105566329A (zh) | 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |